Elanco Animal Health Incorporated
ELAN
Rang in Aktien
#1841
Elanco Animal Health, a firm dedicated to animal well-being, creates, produces,... Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.
Aktienkurs
$23.12
Marktkapitalisierung
$11.55B
Veränderung (1 Tag)
-1.64%
Veränderung (1 Jahr)
6.45%
Land
US
Handel Elanco Animal Health Incorporated (ELAN)
Kategorie
Healthcare
Gewinn für Elanco Animal Health Incorporated (ELAN)
Gewinn im Jun 2026 TTM: $-166.00M
Laut den aktuellen Finanzberichten von Elanco Animal Health Incorporated betragen die aktuellen Gewinne des Unternehmens $-166.00M. Im Jahr 2023 erzielte das Unternehmen einen Gewinn von $-1.20B, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2022, der $-72.00M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Elanco Animal Health Incorporated von 2015 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $-166.00M | -134.02% |
| 2024 | $488.00M | -140.84% |
| 2023 | $-1.20B | 1,559.72% |
| 2022 | $-72.00M | -87.39% |
| 2021 | $-571.00M | -15.03% |
| 2020 | $-672.00M | -959.34% |
| 2019 | $78.20M | -31.46% |
| 2018 | $114.10M | -149.05% |
| 2017 | $-232.60M | 938.39% |
| 2016 | $-22.40M | -91.37% |
| 2015 | $-259.50M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | -1,162.98% |
IN
|
